| Lung Non-Squamous Non-Small Cell Carcinoma altered in cohorts of …ALTERED_INderived200 of 492show all (up to 200) |
|---|
| ← altered in cohorts of | RYR2 413 / 573 cases (72 %) · ssm · TCGA-LUAD · largest of 11 cohorts | — | — | Lung Adenocarcinoma | 11 | Observed | gdc | graph → |
| ← altered in cohorts of | FLG 406 / 573 cases (71 %) · ssm · TCGA-LUAD · largest of 9 cohorts | — | — | Lung Adenocarcinoma | 9 | Observed | gdc | graph → |
| ← altered in cohorts of | USH2A 402 / 573 cases (70 %) · ssm · TCGA-LUAD · largest of 11 cohorts | — | — | Lung Adenocarcinoma | 11 | Observed | gdc | graph → |
| ← altered in cohorts of | PRPF3 35 / 50 cases (70 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPTA1 400 / 573 cases (70 %) · ssm · TCGA-LUAD · largest of 11 cohorts | — | — | Lung Adenocarcinoma | 11 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR3A 60 / 87 cases (69 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HSPA6 60 / 87 cases (69 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ANP32E 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | APH1A 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf54 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CA14 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CIART 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTXND2 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRPS21 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTX1 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR2B 59 / 87 cases (68 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR3B 59 / 87 cases (68 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FLG2 388 / 573 cases (68 %) · ssm · TCGA-LUAD · largest of 8 cohorts | — | — | Lung Adenocarcinoma | 8 | Observed | gdc | graph → |
| ← altered in cohorts of | CSMD3 383 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 9 cohorts | — | — | Lung Adenocarcinoma | 9 | Observed | gdc | graph → |
| ← altered in cohorts of | HRNR 383 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 8 cohorts | — | — | Lung Adenocarcinoma | 8 | Observed | gdc | graph → |
| ← altered in cohorts of | ASH1L 382 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CD84 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR2A 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRLA 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRLB 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GATAD2B 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | JTB 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | RAB13 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPS27 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF6 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC39A1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TNN 382 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 6 cohorts | — | — | Lung Adenocarcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | TNR 382 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 6 cohorts | — | — | Lung Adenocarcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | UAP1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UHMK1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HMCN1 379 / 573 cases (66 %) · ssm · TCGA-LUAD · largest of 8 cohorts | — | — | Lung Adenocarcinoma | 8 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf56 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM189B 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GABPB2 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYSMD1 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEKHO1 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMD4 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RFX5 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMOD4 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFAIP8L2 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS72 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC16 376 / 573 cases (66 %) · ssm · TCGA-LUAD · largest of 11 cohorts | — | — | Lung Adenocarcinoma | 11 | Observed | gdc | graph → |
| ← altered in cohorts of | ATF6 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf189 57 / 87 cases (66 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf226 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD48 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DAP3 57 / 87 cases (66 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | DCST2 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDR2 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DPM3 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DUSP12 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA4 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HAX1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGSF8 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL6R 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ILF2 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INTS3 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNJ10 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNJ9 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LY9 57 / 87 cases (66 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NOS1AP 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | S100A1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | S100A13 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D1B 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF7 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC27A3 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SNAPIN 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPATA46 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CACNA1E 374 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 9 cohorts | — | — | Lung Adenocarcinoma | 9 | Observed | gdc | graph → |
| ← altered in cohorts of | PAPPA2 374 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 9 cohorts | — | — | Lung Adenocarcinoma | 9 | Observed | gdc | graph → |
| ← altered in cohorts of | TCHH 374 / 573 cases (65 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASTN1 373 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 6 cohorts | — | — | Lung Adenocarcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNN3 372 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ASPM 371 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 7 cohorts | — | — | Lung Adenocarcinoma | 7 | Observed | gdc | graph → |
| ← altered in cohorts of | NUP210L 371 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAR 370 / 573 cases (65 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP8B2 370 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL5 370 / 573 cases (65 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AQP10 369 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NPR1 369 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | PKLR 369 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGAP30 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP1A4 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CRABP2 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CRP 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECM1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GLMP 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GOLPH3L 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HAPLN2 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ITLN1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KHDC4 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHDC9 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAMTOR2 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MCL1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MLLT11 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PAQR6 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIGM 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMB4 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SELENBP1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF9 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBE2Q1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBQLN4 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP21 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS45 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | VSIG8 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BRINP3 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 6 cohorts | — | — | Lung Adenocarcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | CHRNB2 368 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHTOP 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CLK2 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | DENND4B 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | IQGAP3 368 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PBXIP1 368 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PEAR1 368 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PI4KB 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PRUNE1 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | RPTN 368 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEMA6C 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SETDB1 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | SMG5 368 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TCHHL1 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ZFHX4 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 10 cohorts | — | — | Lung Adenocarcinoma | 10 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAMTSL4 367 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ANXA9 367 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | CTSK 367 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | FLAD1 367 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HCN3 367 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KPRP 367 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LINGO4 367 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OTUD7B 367 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RUSC1 367 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | STYXL2 367 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | TDRD10 367 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TPM3 367 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | UBAP2L 367 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | KRTCAP2 32 / 50 cases (64 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC1 32 / 50 cases (64 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OR10R2 32 / 50 cases (64 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINC1 32 / 50 cases (64 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARNT 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | BCAN 366 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDC42SE1 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CERS2 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CGN 366 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CREB3L4 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | CRTC2 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | CTSS 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | DCST1 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | FDPS 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GBA 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GON4L 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MINDY1 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NES 366 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OR10Z1 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PIP5K1A 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | POGZ 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | RPRD2 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC50A1 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SV2A 366 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TARS2 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | THBS3 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | THEM5 366 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRIM46 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | YY1AP1 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF687 366 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAM15 365 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | BNIPL 365 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf43 365 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | CELF3 365 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA3 365 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL2 365 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL3 365 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HORMAD1 365 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | INSRR 365 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MSTO1 365 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | OLFML2B 365 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | RIT1 365 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | S100A16 365 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | S100A5 365 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | S100A7 365 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SCAMP3 365 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | SCNM1 365 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SHE 365 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SYT11 365 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP1A2 31 / 50 cases (62 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ENSA 31 / 50 cases (62 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAX1 31 / 50 cases (62 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LCE1F 31 / 50 cases (62 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OR6K2 31 / 50 cases (62 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TP53 1,429 / 2,653 cases (54 %) · ssm · luad_mskcc_2023_met_organotropism · largest of 17 cohorts | — | — | Lung Adenocarcinoma | 17 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TTN 272 / 566 cases (48 %) · ssm · luad_tcga_pan_can_atlas_2018 · largest of 12 cohorts | — | — | Lung Adenocarcinoma | 12 | Observed | cbioportal | graph → |
| ← altered in cohorts of | LRP1B 201 / 566 cases (36 %) · ssm · luad_tcga_pan_can_atlas_2018 · largest of 9 cohorts | — | — | Lung Adenocarcinoma | 9 | Observed | cbioportal | graph → |
| ← altered in cohorts of | EGFR 866 / 2,653 cases (33 %) · ssm · luad_mskcc_2023_met_organotropism · largest of 16 cohorts | — | — | Lung Adenocarcinoma | 16 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KRAS 787 / 2,653 cases (30 %) · ssm · luad_mskcc_2023_met_organotropism · largest of 13 cohorts | — | — | Lung Adenocarcinoma | 13 | Observed | cbioportal | graph → |